Provectus Biopharmaceuticals Inc (PVCT)
0.1948
0.00 (0.00%)
USD |
OTCM |
Apr 19, 15:58
Provectus Biopharmaceuticals Enterprise Value: 84.71M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 84.71M |
| April 17, 2024 | 82.61M |
| April 16, 2024 | 78.37M |
| April 15, 2024 | 73.17M |
| April 12, 2024 | 73.13M |
| April 11, 2024 | 79.21M |
| April 10, 2024 | 74.09M |
| April 09, 2024 | 70.02M |
| April 08, 2024 | 63.55M |
| April 05, 2024 | 65.41M |
| April 04, 2024 | 67.19M |
| April 03, 2024 | 69.98M |
| April 02, 2024 | 76.15M |
| April 01, 2024 | 82.65M |
| March 28, 2024 | 79.61M |
| March 27, 2024 | 86.80M |
| March 26, 2024 | 85.54M |
| March 25, 2024 | 86.80M |
| March 22, 2024 | 82.86M |
| March 21, 2024 | 85.96M |
| March 20, 2024 | 86.76M |
| March 19, 2024 | 85.75M |
| March 18, 2024 | 86.80M |
| March 15, 2024 | 93.88M |
| March 14, 2024 | 87.81M |
| Date | Value |
|---|---|
| March 13, 2024 | 89.64M |
| March 12, 2024 | 92.51M |
| March 11, 2024 | 88.28M |
| March 08, 2024 | 86.28M |
| March 07, 2024 | 92.34M |
| March 06, 2024 | 74.22M |
| March 05, 2024 | 73.53M |
| March 04, 2024 | 73.67M |
| March 01, 2024 | 69.18M |
| February 29, 2024 | 65.28M |
| February 28, 2024 | 64.17M |
| February 27, 2024 | 63.73M |
| February 26, 2024 | 63.18M |
| February 23, 2024 | 62.49M |
| February 22, 2024 | 63.69M |
| February 21, 2024 | 62.47M |
| February 20, 2024 | 62.28M |
| February 16, 2024 | 61.19M |
| February 15, 2024 | 59.85M |
| February 14, 2024 | 60.12M |
| February 13, 2024 | 58.88M |
| February 12, 2024 | 56.89M |
| February 09, 2024 | 60.25M |
| February 08, 2024 | 57.44M |
| February 07, 2024 | 57.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
19.33M
Minimum
Oct 19 2022
93.88M
Maximum
Mar 15 2024
42.68M
Average
43.66M
Median
Enterprise Value Benchmarks
| Insmed Inc | 4.057B |
| NeuroMetrix Inc | -10.75M |
| Intra-Cellular Therapies Inc | 6.476B |
| Rhythm Pharmaceuticals Inc | 2.016B |
| Amylyx Pharmaceuticals Inc | -237.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.6634M |
| Total Expenses (Quarterly) | 0.629M |
| Earnings Yield | -2.98% |